Immunosenescence Study of T Cells: A Systematic Review

Rodríguez, Isidro Hernández; Ruiz, Nicolás Lalinde; León, Manuela Llano; Enríquez, Laura Martínez; Velásquez, María del Pilar Montilla; Ortiz-Aguirre, Juan Pablo; Bohórquez, Oscar Mauricio Rodríguez; Vargas, Esteban Alejandro Velandia; Hernández, Elkin; López, Carlos

doi:10.3389/fimmu.2020.604591

Cited by 107 publications

(100 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CD28 – CD8 + T cells are late-differentiated cells, known to express combinations of NK receptors, such as CD56, NKG2A, and KIRs, as well as inhibitory receptors and markers of terminal differentiation, including PD-1, CD57, and LAG3 ( 45 ). Expression of these inhibitory factors and increasing abundance with age have led to suggestions that these cells have reduced immunostimulatory capacity and are associated with immune senescence ( 46 ). While early studies found reduced proliferative ability compared with CD28 + cells ( 47 ), more recent studies have shown similar proliferative ability between CD28 + and CD28 – CD8 + T cells ( 48 , 49 ).…”

Section: Discussionmentioning

confidence: 99%

NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant

Pickering¹,

Sen²,

Arakawa-Hoyt³

et al. 2021

JCI Insight

View full text Add to dashboard Cite

Cytomegalovirus (CMV) causes mostly asymptomatic but lifelong infection. Primary infection or reactivation in immunocompromised individuals can be life-threatening. CMV viremia often occurs in solid organ transplant (SOT) recipients and associates with decreased graft survival and higher mortality. Furthering understanding of impaired immunity allowing CMV reactivation is critical to guiding anti-viral therapy and examining CMV's impact on outcomes of SOT. This study characterized longitudinal immune responses to CMV in 31 kidney transplant recipients with CMV viremia and matched, non-viremic recipients. Subjects were sampled three-and twelve-months post-transplant, with additional samples oneweek and one-month post-viremia. Peripheral blood mononuclear cells (PBMC) were stained for NK and T cell markers. PBMC transcriptomes were characterized by RNA-Seq. Plasma proteins were quantified by Luminex. CD8 T cell transcriptomes were characterized by single-cell RNA-Seq. Pre-viremia, patients had high levels of IL-15 with concurrent expansion of immature CD56 bright NK cells. Post-viremia, mature CD56 dim NK cells and CD28 -CD8 T cells upregulating inhibitory and NK-associated receptors were expanded. Memory NK cells and NK-like CD28 -CD8 T cells were associated with control of viremia. These findings suggest signatures of innate activation may be prognostic for CMV reactivation posttransplant, while CD8 T cell functionality is critical for effective control of CMV.

show abstract

Section: Discussionmentioning

confidence: 99%

NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant

Pickering¹,

Sen²,

Arakawa-Hoyt³

et al. 2021

JCI Insight

View full text Add to dashboard Cite

show abstract

“…These changes can be divided into those affecting the abundance of different subpopulations and those influencing the functional capacity of these cells. Concerning the first ones, immunosenescence has been linked to an inverted ratio CD4/CD8 and with the accumulation of T memory cells, among many others, which were recently reviewed [ 47 , 48 , 49 ]. These changes are thought to be the result of the immunological history of the individual and, as such, an adaptation to the circumstances in the old [ 46 ] (i.e., the higher need of T CD8 cytotoxic cells due to increased cancerous cells, or no need to maintain the T naïve cell repertoire, given the little chance of discovering a new antigen at the very old age).…”

Section: Impact Of Immunosenescence In Oxi-inflamm-agingmentioning

confidence: 99%

The Role of Immune Cells in Oxi-Inflamm-Aging

Toda

Ceprián

Cerro

et al. 2021

Cells

View full text Add to dashboard Cite

Aging is the result of the deterioration of the homeostatic systems (nervous, endocrine, and immune systems), which preserve the organism’s health. We propose that the age-related impairment of these systems is due to the establishment of a chronic oxidative stress situation that leads to low-grade chronic inflammation throughout the immune system’s activity. It is known that the immune system weakens with age, which increases morbidity and mortality. In this context, we describe how the function of immune cells can be used as an indicator of the rate of aging of an individual. In addition to this passive role as a marker, we describe how the immune system can work as a driver of aging by amplifying the oxidative-inflammatory stress associated with aging (oxi-inflamm-aging) and inducing senescence in far tissue cells. Further supporting our theory, we discuss how certain lifestyle conditions (such as social environment, nutrition, or exercise) can have an impact on longevity by affecting the oxidative and inflammatory state of immune cells, regulating immunosenescence and its contribution to oxi-inflamm-aging.

show abstract

“…Aging is frequently accompanied by immunosenescence, a reduction in function of the innate and adaptive immune systems [ 190 ]. In particular, a paucity of recent thymocyte emigrants, as well as changes in B cells [ 191 ] and CD4+ and CD8+ T cells [ 191 , 192 ] in patients with MS can compound the immunosuppressive effect of some DMTs [ 193 ]. The well-established safety profile of IFN β DMTs suggests its potential usefulness in older patients, particularly those with comorbidities, the risks of which might be heightened by certain MS therapies.…”

Section: The Role Of Im Ifn β-1a In the Current Ms Therapeutic Landscapementioning

confidence: 99%

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)

et al. 2021

View full text Add to dashboard Cite

Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS) in 1993. Since that time, clinical trials and real-world observational studies have demonstrated the effectiveness of IFN therapies. The pivotal intramuscular IFN β-1a phase III trial published in 1996 was the first to demonstrate that a DMT could reduce accumulation of sustained disability in MS. Patient adherence to treatment is higher with intramuscular IFN β-1a, given once weekly, than with subcutaneous formulations requiring multiple injections per week. Moreover, subcutaneous IFN β-1a is associated with an increased incidence of injection-site reactions and neutralizing antibodies compared with intramuscular administration. In recent years, revisions to MS diagnostic criteria have improved clinicians’ ability to identify patients with MS and have promoted the use of magnetic resonance imaging (MRI) for diagnosis and disease monitoring. MRI studies show that treatment with IFN β-1a, relative to placebo, reduces T2 and gadolinium-enhancing lesions and gray matter atrophy. Since the approval of intramuscular IFN β-1a, a number of high-efficacy therapies have been approved for MS, though the benefit of these high-efficacy therapies should be balanced against the increased risk of serious adverse events associated with their long-term use. For some subpopulations of patients, including pregnant women, the safety profile of IFN β formulations may provide a particular benefit. In addition, the antiviral properties of IFNs may indicate potential therapeutic opportunities for IFN β in reducing the risk of viral infections such as COVID-19.

show abstract

Immunosenescence Study of T Cells: A Systematic Review

Cited by 107 publications

References 69 publications

NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant

NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant

The Role of Immune Cells in Oxi-Inflamm-Aging

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)

Contact Info

Product

Resources

About